its about resetting your relationship with hunger and fullness
The Danish diabetes and obesity giant Novo Nordisks (NOV: N) GLP-1 receptor agonist is already approved for use in the treatment of obesity and for weight management, to be used alongside diet, physical activity and behavioural support
However, the FDA has scheduled a Pharmacy Compounding Advisory Committee (PCAC) meeting for July 2324, 2026 to discuss whether BPC-157 should potentially be added to the 503A Bulks List
Myth #5: It Only Works If You Have Diabetes The Claim: These drugs are for diabetics, if you dont have diabetes they wont work for weight loss (Facebook group comment) The Reality: Retatrutides Phase 2 trial specifically enrolled participants without diabetes, and they achieved 24.2% average weight loss
We demonstrated that the TSS pathway is ineffective in supraphysiological cystine concentrations but is critical under physiological cystine supplementation or excess hemin exposure in SCD erythroblasts
It contains the 3.3kb lag-2 promoter, the apx-1 cDNA, and the 1kb 3 UTR of lag-2
